Mercato chiuso -
Altri mercati azionari
|
Variaz. 5gg | Var. 1 gen. | ||
23,25 USD | -1,19% | -7,92% | +14,76% |
15/04 | 4D MOLECULAR THERAPEUTICS, INC. : Barclays conferma il rating Buy | ZM |
15/04 | 4D MOLECULAR THERAPEUTICS, INC. : RBC Capital Markets ottimista sul caso | ZM |
Attività
Numero di dipendenti: 147
Vendite per attività
USD in Milioni | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
Gene Therapeutic Products
100,0
%
| 3 | 100,0 % | 21 | 100,0 % | +562,29% |
Vendite per regione
USD in Milioni | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
United States
97,3
%
| 0 | 1,1 % | 20 | 97,3 % | +57.488,57% |
Netherlands
2,7
%
| 3 | 98,9 % | 1 | 2,7 % | -81,67% |
Dirigenti
Dirigenti | Titolo | Età | Da |
---|---|---|---|
Theresa Janke
FOU | Founder | 49 | 12/09/13 |
David Kirn
FOU | Founder | 62 | 12/09/13 |
Uneek Mehra
DFI | Director of Finance/CFO | - | 12/09/23 |
Fariborz Kamal
PSD | President | 61 | 01/10/18 |
Robert Kim
CTO | Chief Tech/Sci/R&D Officer | 63 | 01/10/22 |
Chief Tech/Sci/R&D Officer | 62 | 23/09/22 | |
Julian Pei
IRC | Investor Relations Contact | - | - |
Scott Bizily
HRO | Human Resources Officer | 52 | 01/09/21 |
An Song
PRN | Corporate Officer/Principal | - | 01/09/21 |
Amministratori
Amministratori | Titolo | Età | Da |
---|---|---|---|
John Milligan
CHM | Chairman | 63 | 01/08/20 |
Susannah Gray
BRD | Director/Board Member | 63 | 01/07/20 |
Charles Theuer
BRD | Director/Board Member | 60 | 01/01/16 |
David Kirn
FOU | Founder | 62 | 12/09/13 |
Jacob Chacko
BRD | Director/Board Member | 45 | 01/03/19 |
Shawn Tomasello
BRD | Director/Board Member | 65 | 18/11/20 |
Director/Board Member | 65 | 18/11/20 | |
Chief Tech/Sci/R&D Officer | 62 | 23/09/22 |
Classe di azioni
Voto | Quantità | Flottante | Autocontrollo | Flottante totale | |
---|---|---|---|---|---|
Azione A | 1 | 51 157 472 | 49 349 028 ( 96,46 %) | 0 | 96,46 % |
Coordinate società
4D Molecular Therapeutics, Inc.
5858 Horton Street Suite 455
94608, Emeryville
+
http://www.4dmoleculartherapeutics.comSettore
Vendite per regione
Revisioni EPS
Variaz. 1 gen. | Capi. | |
---|---|---|
+14,76% | 1,19 Mrd | |
+1,51% | 42,75 Mrd | |
+49,22% | 41,61 Mrd | |
+8,57% | 41,34 Mrd | |
-12,36% | 26,59 Mrd | |
+8,92% | 25,49 Mrd | |
-25,13% | 18,12 Mrd | |
+29,17% | 12,24 Mrd | |
-3,12% | 11,76 Mrd | |
+6,35% | 11 Mrd |
- Borsa valori
- Azioni
- Azione FDMT
- Società 4D Molecular Therapeutics, Inc.